1 Epidemiology and Preventive Medicine, National and Kapodistrian University of Athens Medical School, Athens, Greece.
2 Barcelona Institute for Global Health (ISGlobal), Hospital Clínic, University of Barcelona, Barcelona, Spain.
3 First Department of Internal Medicine, Medical School of National & Kapodistrian University of Athens, Laiko General Hospital, Athens, Greece.
4 Institute of Health Sciences - Católica University of Portugal, Lisboa, Portugal.
5 Faculty of Health, Medicine and Life Sciences - Maastricht University, Maastricht, The Netherlands.
6 Department of Virology, Erasmus Medical Centre, University Medical Centre Rotterdam, Rotterdam, The Netherlands.
7 European Parliament, Brussels, Belgium.
8 Université Paris Diderot, Sorbonne Paris Cité, Paris, France.
9 Université Lille, Inserm, - Lille Inflammation Research International Center, Lille, France.
10 Institute for Technology Assessment, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
11 Endemic Medicine and HepatoGastroenterology Department, Faculty of Medicine, Cairo University, Cairo, Egypt.
12 Badr University in Cairo, Cairo, Egypt.
13 School of Health and Life Sciences, Glasgow Caledonian University, Glasgow, UK.
14 Health Protection Scotland, Glasgow, UK.
15 National and Kapodistrian University of Athens-Eginition Hospital, Athens, Greece.
16 Clinic for Infectious Diseases and Febrile Illnesses, University Medical Centre Ljubljana, Ljubljana, Slovenia.
17 Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
18 WHO Regional Office for Europe, Brussels, Belgium.
19 Divisions of Gastroenterology and Hepatology and of Clinical Pathology, University Hospitals, Geneva, Switzerland.
20 Socialist International, London, UK.
21 Department of Gastroenterology, Medical School of National and Kapodistrian University of Athens, Athens, Greece.
22 Department of Internal Medicine & Gastroenterology (IMuG) Hepatology, Endocrinology, Rheumatology and Nephrology with Centralized Emergency Department (ZAE), Klagenfurt, Austria.
23 Center for Disease Analysis Foundation, Lafayette, CO, USA.
24 European Liver Patients' Association (ELPA), Brussels, Belgium.
25 Correlation European Harm Reduction Network, Amsterdam, The Netherlands.
26 Department of Gastroenterology, Acibadem Mehmet Ali Aydinlar University School of Medicine, Istanbul, Turkey.
27 Department of Medicine, Inova Fairfax Medical Campus, Falls Church, VA, USA.
28 Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School (MHH), Hannover, Germany.
The majority of people infected with chronic hepatitis C virus (HCV) in the European Union (EU) remain undiagnosed and untreated. During recent years, immigration to EU has further increased HCV prevalence. It has been estimated that, out of the 4.2 million adults affected by HCV infection in the 31 EU/ European Economic Area (EEA) countries, as many as 580 000 are migrants. Additionally, HCV is highly prevalent and under addressed in Eastern Europe. In 2013, the introduction of highly effective treatments for HCV with direct-acting antivirals created an unprecedented opportunity to cure almost all patients, reduce HCV transmission and eliminate the disease. However, in many settings, HCV elimination poses a serious challenge for countries' health spending. On 6 June 2018, the Hepatitis B and C Public Policy Association held the 2nd EU HCV Policy summit. It was emphasized that key stakeholders should work collaboratively since only a few countries in the EU are on track to achieve HCV elimination by 2030. In particular, more effort is needed for universal screening. The micro-elimination approach in specific populations is less complex and less costly than country-wide elimination programmes and is an important first step in many settings. Preliminary data suggest that implementation of the World Health Organization (WHO) Global Health Sector Strategy on Viral Hepatitis can be cost saving. However, innovative financing mechanisms are needed to raise funds upfront for scaling up screening, treatment and harm reduction interventions that can lead to HCV elimination by 2030, the stated goal of the WHO.